OncoMatch/Clinical Trials/NCT06572605
External Beam Radiation Therapy in Combination With Talquetamab for the Treatment of Multiple Myeloma Patients With Extramedullary Disease
Is NCT06572605 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies Talquetamab for extramedullary disease in multiple myeloma.
Treatment: Talquetamab — This phase I/II trial tests the safety and effectiveness of extramedullary disease (EMD)-directed external beam radiation therapy (EBRT) in combination with talquetamab for the treatment of multiple myeloma patients with extramedullary disease. Extramedullary disease in multiple myeloma involves the infiltration of organs and soft tissues by malignant plasma cells and has proven difficult to treat. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink cancers. EBRT is a type of radiation therapy that delivers high-energy beams to the cancer from outside of the body. In this trial, the EBRT will be directed to a site of extramedullary disease. Talquetamab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Combining EMD-directed EBRT with talquetamab may be safe, tolerable, and/or effective in treating multiple myeloma patients with extramedullary disease.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Prior therapy
Must have received: immunomodulatory agent
Subject must have received an immunomodulatory agent
Must have received: proteasome inhibitor
Subject must have received a proteasome inhibitor
Must have received: anti-CD38 antibody
Subject must have received an anti-CD38 antibody
Cannot have received: irradiation to target EMD site or field
Prior irradiation to target EMD site or field
Cannot have received: GPRC5D therapy
Prior GPRC5D therapy
Cannot have received: radiopharmaceutical therapy
Prior radiopharmaceutical therapy
Cannot have received: external beam radiotherapy to > 25% of bone marrow
Patients who have received previous radiation to > 25% of their bone marrow
Cannot have received: allogeneic hematopoietic cell transplantation
Exception: within the past 6 months
Prior allogeneic hematopoietic cell transplantation within the past 6 months
Cannot have received: autologous hematopoietic cell transplantation
Exception: within the past 12 weeks
Prior autologous hematopoietic cell transplantation within the past 12 weeks
Lab requirements
Blood counts
ANC 1,000/mm^3 (no G-CSF/GM-CSF support for 7 days, no pegylated GCSF for 14 days); Platelets 50,000/mm^3 (no transfusion/thrombopoietin receptor agonist within 7 days); Hemoglobin 8g/dL (no transfusion/erythropoietin within 7 days)
Kidney function
Creatinine clearance of 30 mL/min per 24 hour urine test or the Cockcroft-Gault formula
Liver function
Total bilirubin 2.0 X ULN (unless has congenital bilirubinemia such as Gilbert's disease, in which case 1.5 d ULN is required); AST 2.5 x ULN; ALT 2.5 x ULN
ANC 1,000/mm^3... Platelets 50,000/mm^3... Hemoglobin 8g/dL... Total bilirubin 2.0 X ULN... AST 2.5 x ULN... ALT 2.5 x ULN... Creatinine clearance of 30 mL/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope Medical Center · Duarte, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify